We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Maravai LifeSciences Holdings, Inc. (MRVI) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Maravai LifeSciences Holdings, Inc. (MRVI - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Maravai LifeSciences Holdings, Inc. is a member of our Medical group, which includes 1112 different companies and currently sits at #12 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Maravai LifeSciences Holdings, Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for MRVI's full-year earnings has moved 9.1% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, MRVI has returned 53.1% so far this year. Meanwhile, the Medical sector has returned an average of -5.7% on a year-to-date basis. As we can see, Maravai LifeSciences Holdings, Inc. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Repligen (RGEN - Free Report) . The stock has returned 39.8% year-to-date.
Over the past three months, Repligen's consensus EPS estimate for the current year has increased 5.2%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Maravai LifeSciences Holdings, Inc. is a member of the Medical - Products industry, which includes 89 individual companies and currently sits at #195 in the Zacks Industry Rank. Stocks in this group have lost about 2% so far this year, so MRVI is performing better this group in terms of year-to-date returns.
On the other hand, Repligen belongs to the Medical - Biomedical and Genetics industry. This 510-stock industry is currently ranked #158. The industry has moved -19.7% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Maravai LifeSciences Holdings, Inc. and Repligen as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Maravai LifeSciences Holdings, Inc. (MRVI) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Maravai LifeSciences Holdings, Inc. (MRVI - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Maravai LifeSciences Holdings, Inc. is a member of our Medical group, which includes 1112 different companies and currently sits at #12 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Maravai LifeSciences Holdings, Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for MRVI's full-year earnings has moved 9.1% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, MRVI has returned 53.1% so far this year. Meanwhile, the Medical sector has returned an average of -5.7% on a year-to-date basis. As we can see, Maravai LifeSciences Holdings, Inc. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is Repligen (RGEN - Free Report) . The stock has returned 39.8% year-to-date.
Over the past three months, Repligen's consensus EPS estimate for the current year has increased 5.2%. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, Maravai LifeSciences Holdings, Inc. is a member of the Medical - Products industry, which includes 89 individual companies and currently sits at #195 in the Zacks Industry Rank. Stocks in this group have lost about 2% so far this year, so MRVI is performing better this group in terms of year-to-date returns.
On the other hand, Repligen belongs to the Medical - Biomedical and Genetics industry. This 510-stock industry is currently ranked #158. The industry has moved -19.7% year to date.
Going forward, investors interested in Medical stocks should continue to pay close attention to Maravai LifeSciences Holdings, Inc. and Repligen as they could maintain their solid performance.